These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Peripheral Hybrid CB Zawatsky CN; Park JK; Abdalla J; Kunos G; Iyer MR; Cinar R Front Endocrinol (Lausanne); 2021; 12():744857. PubMed ID: 34650521 [TBL] [Abstract][Full Text] [Related]
4. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. Cinar R; Iyer MR; Liu Z; Cao Z; Jourdan T; Erdelyi K; Godlewski G; Szanda G; Liu J; Park JK; Mukhopadhyay B; Rosenberg AZ; Liow JS; Lorenz RG; Pacher P; Innis RB; Kunos G JCI Insight; 2016 Jul; 1(11):. PubMed ID: 27525312 [TBL] [Abstract][Full Text] [Related]
5. Endocannabinoid signalling/cannabinoid receptor 2 is involved in icariin-mediated protective effects against bleomycin-induced pulmonary fibrosis. Du W; Zhang T; Yang F; Gul A; Tang Z; Zhang H; Jiang S; Wang S; Dong J Phytomedicine; 2022 Aug; 103():154187. PubMed ID: 35667261 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB Iyer MR; Cinar R; Katz A; Gao M; Erdelyi K; Jourdan T; Coffey NJ; Pacher P; Kunos G J Med Chem; 2017 Feb; 60(3):1126-1141. PubMed ID: 28085283 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms. Roger C; Buch C; Muller T; Leemput J; Demizieux L; Passilly-Degrace P; Cinar R; Iyer MR; Kunos G; Vergès B; Degrace P; Jourdan T Diabetes; 2020 Oct; 69(10):2120-2132. PubMed ID: 32680936 [TBL] [Abstract][Full Text] [Related]
8. An Integrative Multiomics Framework for Identification of Therapeutic Targets in Pulmonary Fibrosis. Arif M; Basu A; Wolf KM; Park JK; Pommerolle L; Behee M; Gochuico BR; Cinar R Adv Sci (Weinh); 2023 Jun; 10(16):e2207454. PubMed ID: 37038090 [TBL] [Abstract][Full Text] [Related]
9. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Kim TH; Lee YH; Kim KH; Lee SH; Cha JY; Shin EK; Jung S; Jang AS; Park SW; Uh ST; Kim YH; Park JS; Sin HG; Youm W; Koh ES; Cho SY; Paik YK; Rhim TY; Park CS Am J Respir Crit Care Med; 2010 Sep; 182(5):633-42. PubMed ID: 20463180 [TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of second and third generation CB Cinar R; Iyer MR; Kunos G Pharmacol Ther; 2020 Apr; 208():107477. PubMed ID: 31926199 [TBL] [Abstract][Full Text] [Related]
11. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Baran CP; Opalek JM; McMaken S; Newland CA; O'Brien JM; Hunter MG; Bringardner BD; Monick MM; Brigstock DR; Stromberg PC; Hunninghake GW; Marsh CB Am J Respir Crit Care Med; 2007 Jul; 176(1):78-89. PubMed ID: 17431224 [TBL] [Abstract][Full Text] [Related]
12. Establishment of the mouse model of acute exacerbation of idiopathic pulmonary fibrosis. Wei YR; Qiu H; Wu Q; Du YK; Yin ZF; Chen SS; Jin YP; Zhao MM; Wang C; Weng D; Li HP Exp Lung Res; 2016; 42(2):75-86. PubMed ID: 27070485 [TBL] [Abstract][Full Text] [Related]
13. Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. Gurujeyalakshmi G; Wang Y; Giri SN Nitric Oxide; 2000 Aug; 4(4):399-411. PubMed ID: 10944425 [TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. Bei Y; Hua-Huy T; Duong-Quy S; Nguyen VH; Chen W; Nicco C; Batteux F; Dinh-Xuan AT Pulm Pharmacol Ther; 2013 Dec; 26(6):635-43. PubMed ID: 23928001 [TBL] [Abstract][Full Text] [Related]
15. Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-κB dependant TGF-β activation: a biphasic experimental study. Chitra P; Saiprasad G; Manikandan R; Sudhandiran G Toxicol Lett; 2013 May; 219(2):178-93. PubMed ID: 23523906 [TBL] [Abstract][Full Text] [Related]
17. Lung fibrosis-associated soluble mediators and bronchoalveolar lavage from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts. Bouros E; Filidou E; Arvanitidis K; Mikroulis D; Steiropoulos P; Bamias G; Bouros D; Kolios G Pulm Pharmacol Ther; 2017 Oct; 46():78-87. PubMed ID: 28865842 [TBL] [Abstract][Full Text] [Related]
18. Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via the inhibition of inducible nitric oxide synthase expression and the TGF-β/Smad signaling pathway. Liu L; Lu W; Ma Z; Li Z Int J Mol Med; 2012 May; 29(5):815-22. PubMed ID: 22367596 [TBL] [Abstract][Full Text] [Related]
19. Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: Decisive role of Bax, Nrf2, NF-κB, Muc5ac, TNF-α and IL-1β. Kandhare AD; Bodhankar SL; Mohan V; Thakurdesai PA Chem Biol Interact; 2015 Jul; 237():151-65. PubMed ID: 26093215 [TBL] [Abstract][Full Text] [Related]
20. Exogenous nitric oxide enhances the prophylactic effect of aminoguanidine, a preferred iNOS inhibitor, on bleomycin-induced fibrosis in the lung: Implications for the direct roles of the NO molecule in vivo. Chen C; Yun XJ; Liu LZ; Guo H; Liu LF; Chen XL Nitric Oxide; 2017 Nov; 70():31-41. PubMed ID: 28757441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]